Correlation Between Aclaris Therapeutics and Exagen

Can any of the company-specific risk be diversified away by investing in both Aclaris Therapeutics and Exagen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aclaris Therapeutics and Exagen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aclaris Therapeutics and Exagen Inc, you can compare the effects of market volatilities on Aclaris Therapeutics and Exagen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aclaris Therapeutics with a short position of Exagen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aclaris Therapeutics and Exagen.

Diversification Opportunities for Aclaris Therapeutics and Exagen

0.42

Correlation Coefficient

Aclaris Therapeutics  Exagen

Very weak diversification

The 3 months correlation between Aclaris and Exagen is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Aclaris Therapeutics and Exagen Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exagen Inc and Aclaris Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aclaris Therapeutics are associated (or correlated) with Exagen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exagen Inc has no effect on the direction of Aclaris Therapeutics i.e., Aclaris Therapeutics and Exagen go up and down completely randomly.

Pair Corralation between Aclaris Therapeutics and Exagen

Given the investment horizon of 90 days Aclaris Therapeutics is expected to under-perform the Exagen. But the stock apears to be less risky and, when comparing its historical volatility, Aclaris Therapeutics is 2.71 times less risky than Exagen. The stock trades about -0.22 of its potential returns per unit of risk. The Exagen Inc is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  428.00  in Exagen Inc on December 29, 2024 and sell it today you would lose (44.00) from holding Exagen Inc or give up 10.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Aclaris Therapeutics  vs.  Exagen Inc

Aclaris Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aclaris Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Exagen Inc

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Exagen Inc are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Exagen may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Aclaris Therapeutics and Exagen

The main advantage of trading using opposite Aclaris Therapeutics and Exagen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aclaris Therapeutics position performs unexpectedly, Exagen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will offset losses from the drop in Exagen's long position.

The idea behind Aclaris Therapeutics and Exagen Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.